Kotak Mahindra Mutual Fund buys into Molbio Diagnostics

Kotak Mahindra Mutual Fund bought a 2.38% stake in Molbio Diagnostics on September 23, 2026 — a purchase coming just over five weeks after Molbio became a listed company.

Share price ~₹1,270-1,320 around Sept 23-24 (volatile — check live price) · Market value ~₹14,500-14,600 crore · P/E ~65x (per screener.in) — between Dr Lal PathLabs (~57x) and Metropolis Healthcare (~67x), though those two run diagnostic labs while Molbio makes the testing devices and kits, so the comparison isn't exact

What just happened

A block deal is a large share transaction carried out between buyers and sellers on the stock exchange. Here, Kotak Mahindra Mutual Fund bought 27.5 lakh shares (2.38% of Molbio) for ₹361.62 crore, at ₹1,315 per share. The seller was Business Excellence Trust III, a Motilal Oswal-backed investment vehicle that held roughly 11.52% of the company before the sale; it sold 29.96 lakh shares (2.6%) for ₹394.07 crore, bringing its holding down to about 8.92% — but it remained Molbio's largest public shareholder even after the sale. Kotak MF bought most, but not all, of the shares sold; the rest went to other buyers whose identities weren't disclosed. The transaction by itself doesn't establish whether the buyer or seller is positive or negative about Molbio's future — pre-IPO investors reduce holdings over time for many routine portfolio reasons.

What Molbio Diagnostics actually does

Founded in 2000 and headquartered in Verna, Goa, Molbio Diagnostics developed Truenat, a portable molecular testing platform using real-time PCR technology to detect infectious diseases including tuberculosis, HIV, and hepatitis. Truenat is one of only two rapid molecular diagnostic platforms recommended by the WHO for initial tuberculosis diagnosis, and the company says it has accounted for roughly 92% of incremental TB diagnostic installations (outside designated microscopy centres) under India's National Tuberculosis Elimination Programme since 2019 — a strong position in a specific, policy-relevant part of the TB-testing market. The company has also expanded beyond molecular testing through subsidiaries including Prognosys Medical Systems, which makes portable radiology imaging devices under the PRORAD brand, with certain models holding EU Medical Device Regulation certification and US FDA 510(k) clearances.

Why the listing timeline matters here

Molbio listed on NSE and BSE on August 17, 2026, at an IPO price of ₹807 (the issue was subscribed 70.26 times — investors bid for shares worth more than 70x what was on offer). The stock opened at ₹980, a 21.4% first-day gain, then briefly touched a 20% upper circuit near ₹1,509.70 (roughly 87% above the IPO price) in the following weeks, before pulling back into the ₹1,270-1,320 range — still about 60-65% above its IPO price a little over five weeks after listing. That's a large price swing in a short period, worth keeping in mind before drawing conclusions from any single day's move, including this one.

The financials — fast growth, but from a weak recent base

Metric (Q1 FY27, quarter ended Jun 30, 2026) Value YoY change --------- Revenue from operations ₹408.4 crore up from ₹99.7 crore Total income ₹411.5 crore up from ₹100.5 crore EBITDA (operating profit before interest, tax, depreciation) ₹103.7 crore (25.2% margin) — Profit after tax ₹52.7 crore vs a loss a year earlier Truenat test kits sold 62.4 lakh (75% of revenue) —

The very large year-on-year jump needs context: full-year revenue grew from ₹1,027.9 crore in FY25 to ₹1,455.2 crore in FY26 — real growth, but nowhere near as dramatic as Q1 FY27's YoY increase suggests, because Q1 FY26's ₹99.7 crore was an unusually weak comparison quarter. In fact, Q1 FY27's ₹408.4 crore was about 27% lower than Q4 FY26's ₹560.6 crore — management itself has said quarterly revenue is lumpy, moving up or down significantly quarter to quarter depending on the timing of device and test-kit orders, rather than following a smooth trend.

On P/E — a company's share price divided by its per-share profit — Molbio trades at roughly 65x (per screener.in), sitting between Dr Lal PathLabs (~57x) and Metropolis (~67x), despite Molbio being newly listed with Q1 FY27 only its second quarter of public reporting. For reference, screener.in also lists an industry-average P/E of about 36x for Molbio's sector classification — meaningfully lower than all three of these individual stocks, though industry averages like this blend very different sub-businesses and are a rough guide at best. Molbio's PEG ratio (P/E divided by expected earnings growth) of around 0.6 suggests the market may not be overpaying relative to its growth rate, but that figure depends heavily on which growth estimate is used given how new and lumpy its reported earnings are.

A newly-listed stock doesn't mean a new business Molbio's history as a listed company is very short, but its business history isn't — it has operated since 2000 and had 25 years of audited financial history before its IPO. What's genuinely new is its public-market track record: investors have only a few weeks of evidence for how the share price behaves and how management's guidance plays out under daily stock-market trading. That's a different kind of uncertainty than investing in a business with no real operating history.

Management's own guidance (forward-looking, not a promise)

From the company's Q1 FY27 earnings call (September 8, 2026):

- FY27 revenue growth: guided at roughly 25%. - FY27 EBITDA margin: guided at 24-25%. - Device sales: management expects volumes broadly within the company's historical annual range of 2,200-2,600 units — not presented as a precise formal target. - Automation investment: ₹72 crore. - New integrated R&D centre in Bangalore: ₹105 crore. - Subsidiary expansion: Prognosys Medical Systems (portable radiology equipment, PRORAD brand) is being built out as a potential second growth line alongside the core Truenat molecular-diagnostics business.

Should this deal change how you see the stock?

A pre-IPO investor reduced its stake while remaining Molbio's largest public shareholder, and a large mutual fund bought most of what was sold — by itself, this transaction doesn't establish whether the outlook is positive or negative. The more important questions are about the business and its valuation: Molbio has a WHO-recommended position in TB diagnostics closely tied to India's national TB-testing programme, but its stock has only traded publicly for about five weeks and has already moved sharply — from a 20% upper-circuit jump near ₹1,509.70 to a meaningful pullback. The things worth monitoring from here are future revenue growth, profitability, device and test-kit volumes, and whether management meets its own guidance — the current ~65x valuation sits within the same broad band as its closest listed peers (Dr Lal PathLabs and Metropolis), rather than clearly cheaper or more expensive.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://www.whalesbook.com/corporate-news/English/healthcarebiotech/Molbio-Diagnostics-Reports-Q1-FY27-Revenue-Of-Rs-408-Crore/6aa4d959f2017017ae6932e1 - https://hdfcsky.com/news/newly-listed-molbio-diagnostics-posts-rs-52-7-cr-profit-in-q1 - https://www.multibagg.ai/market-pulse/articles/molbio-q1-1680637866 - https://www.multibagg.ai/market-pulse/articles/molbio-diagnostics-q1fy27-earnings-call-cmtogut3i000k2mua0lygl352 - https://www.business-standard.com/markets/news/molbio-diagnostics-hits-20-upper-circuit-on-heavy-volume-up-35-in-2-days-1260910004191.html - https://en.wikipedia.org/wiki/MolbioDiagnostics - https://www.valueresearchonline.com/stocks/386648/molbio-diagnostics-ltd/peer-comparison/ - https://www.screener.in/company/MOLBIO/consolidated/ - https://www.screener.in/company/LALPATHLAB/consolidated/ - https://www.screener.in/company/METROPOLIS/consolidated/